Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

Abstract

Glioblastoma is the most common primary malignant brain tumor of adults and one of the most lethal of all cancers. Patients with this disease have a median survival of 15 months from the time of diagnosis despite surgery, radiation, and chemotherapy. New treatment approaches are needed. Recent works suggest that glioblastoma patients may benefit from molecularly targeted therapies. Here, we address the compelling need for identification of new molecular targets. Leveraging global gene expression data from two independent sets of clinical tumor samples (n ‫؍‬ 55 and n ‫؍‬ 65), we identify a gene coexpression module in glioblastoma that is also present in breast cancer and significantly overlaps with the ''metasignature'' for undifferentiated cancer. Studies in an isogenic model system demonstrate that this module is downstream of the mutant epidermal growth factor receptor, EGFRvIII, and that it can be inhibited by the epidermal growth factor receptor tyrosine kinase inhibitor Erlotinib. We identify ASPM (abnormal spindle-like microcephaly associated) as a key gene within this module and demonstrate its overexpression in glioblastoma relative to normal brain (or body tissues). Finally, we show that ASPM inhibition by siRNA-mediated knockdown inhibits tumor cell proliferation and neural stem cell proliferation, supporting ASPM as a potential molecular target in glioblastoma. Our weighted gene coexpression network analysis provides a blueprint for leveraging genomic data to identify key control networks and molecular targets for glioblastoma, and the principle eluted from our work can be applied to other cancers. epidermal growth factor receptor vIII ͉ Glioblastoma ͉ modules ͉ weighted gene coexpression network analysis ͉ network-based screening

Modulation of Gene Expression and Cell-Cycle Signaling Pathways by the EGFR Inhibitor Gefitinib (Iressa) in Rat Urinary Bladder Cancer

“…Studies suggest that highly centralized "hub" genes in the network architecture are more likely to be key drivers for cellular function (33). Characterization of these hub genes may help to give novel insight into bladder tumorigenesis and to develop additional novel drug targets for bladder cancer.…”

MicroRNA Expression Profile Analysis Reveals Diagnostic Biomarker for Human Prostate Cancer

“…The importance of a gene is often dependent on how well it associates with other genes in a network. Studies suggest that more centralized genes in the network are more likely to be key drivers to proper cellular function than peripheral genes (nodes) (Horvath et al, 2006).…”

The effect of alcohol and nicotine abuse on gene expression in the brain

“…Application of analysis softwares such as DAVID (National Cancer Institute at Frederick; http:// david.abcc.ncifcrf.gov/), Pathway Assist by Stratagene (Agilent Technologies, Santa Clara, CA, USA) and others can indicate underlying biological themes. Recent advances in tools to group genes by variation of expression across individual samples have made possible the exploration of gene networks (109) . This type of analysis has been directed at diverse biological problems, for example, evolution of the human cortex (110) and genes differentially expressed during the progression of Alzheimer's disease (111) .…”